## Approval of exsig™ COVID-19 Direct test in the UK

RNS Number : 5788S Novacyt S.A. 15 July 2022	
Novacyt S.A.	
("Novacyt", the "Company" or the "Group")	
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation	on
Paris, France and Camberley, UK - 15 July 2022 - Novacyt (EURONEXT Cinternational specialist in clinical diagnostics, announces that the Competer PCR test has been approved in the UK under the UK Health Security Age Device Approvals) (Amendment) Regulations 2021 ("CTDA").	pany's exsig™ COVID-19 Direct Real-Time
The exsig™ COVID-19 Direct Real-Time PCR test is designed to detect a and, as with all the Company's direct-to-PCR products, removes the nees solutions to significantly improve laboratory workflow and reduce costs an open platform, meaning it can be used with the Company's q16 and systems. The test is the Company's fifth PCR product to be added to the	ed for manual or automated extraction s. In addition, the test is designed for use or q32 instruments, as well as other validated
David Allmond, Group CEO of Novacyt, commented:	
"To ensure Novacyt is well positioned for any future COVID-19 outbreak portfolio. The approval of exsig™ COVID-19 Direct supports this aim, co portfolio for COVID-19 testing in the UK and further reinforcing Novacyt diseases."	mplementing the Company's existing PCR
The status of current CTDA submissions is as follows:	
# Product name	Current CTDA status

Approved November 2021

1 genesig® COVID-19 Real-Time PCR

Approved February 2022
Approved April 2022
Approved May 2022
Approved July 2022
Pending evaluation

- End -

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

 $r.durget to @allegrafinance.com/\ y.pet it @allegrafinance.com$ 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

**About Novacyt Group** 

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

**END** 

**MSCUSSURUUUBAUR**